期刊
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
卷 97, 期 5, 页码 396-399出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/dji045
关键词
-
类别
资金
- NCI NIH HHS [N01-CN-45165] Funding Source: Medline
- CCR NIH HHS [N01-RC-37004, N01-RC-45035] Funding Source: Medline
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study demonstrated a 32% reduction in prostate cancer incidence in response to daily alpha-tocopherol supplementation. We examined baseline serum concentrations of alpha-tocopherol and gamma-tocopherol to compare their respective associations with prostate cancer risk. From the ATBC study cohort of 29 133 Finnish men, 50-69 years old, we randomly selected 100 incident prostate cancer case patients and matched 200 control subjects. Odds ratios and 95% confidence intervals (CIs) were estimated for the serum tocopherols (measured by high-performance liquid chromatography) using logistic regression models. All P values were two-sided. Odds ratios for the highest versus the lowest tertiles were 0.49 (95% CI = 0.24 to 1.01, P-trend =.05) for alpha-tocopherol and 0.57 (95% CI = 0.31 to 1.06, P-trend =.08) for gamma-tocopherol. Further analyses indicated that the association of high serum tocopherols with low prostate cancer risk was stronger in the alpha-tocopherol-supplemented group than in those not receiving alpha-tocopherol. Participants with higher circulating concentrations of the major vitamin E fractions, alpha-tocopherol and gamma-tocopherol, had similarly lower prostate cancer risk.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据